Boston Partners Harrow Health, Inc. Transaction History

Boston Partners

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$13.84 - $21.46 $1.02 Million - $1.58 Million	-73,695 Reduced 64.25%	40,998 $867,000
Q4 2022 Feb 07, 2023	BUY	$10.28 - $14.78 $27,272 - $39,211	2,653 Added 2.37%	114,693 $1.69 Million
Q3 2022 Nov 09, 2022	BUY	$6.57 - $24.88 $14,716 - $55,731	2,240 Added 2.04%	112,040 $1.35 Million
Q2 2022 Aug 10, 2022	BUY	$5.75 - $7.74 $72,944 - $98,189	12,686 Added 13.06%	109,800 $799,000
Q1 2022 May 10, 2022	BUY	$6.77 - $8.66 $99,911 - $127,804	14,758 Added 17.92%	97,114 $662,000
Q4 2021 Feb 04, 2022	SELL	$8.5 - $12.0 $112,905 - $159,396	-13,283 Reduced 13.89%	82,356 $712,000
Q3 2021 Nov 05, 2021	SELL	$6.99 - $10.6 $226,434 - $343,376	-32,394 Reduced 25.3%	95,639 $869,000
Q2 2021 Aug 12, 2021	BUY	$6.68 - $11.07 $39,679 - $65,755	5,940 Added 4.87%	128,033 $1.19 Million
Q1 2021 May 10, 2021	BUY	$6.26 - $11.03 $764,302 - $1.35 Million	122,093 New	122,093 $824,000

177

21.4M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $992M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

Stay updated on Boston Partners with notifications on news.